Gilead Sciences Inc
Latest Gilead Sciences Inc News and Updates
Company & Industry OverviewsWhat Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?
Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees. Company & Industry OverviewsWhy Is AbbVie’s Valuation Multiple Rising in July?
AbbVie believes that the Market has misunderstood the growth potential of Rova-T, which is expected to earn $1.5 billion–$2 billion in peak sales even under extremely conservative assumptions. Earnings ReportWhat’s behind Valeant’s Operating Expenses?
Valeant’s major operating expenses include cost of sales, SG&A (selling, general, and administrative) expenses, and R&D (research and development) costs. Company & Industry OverviewsInside Gilead Sciences’ Involvement in TAF Therapies
On March 01, 2016, the FDA approved Gilead Sciences’ TAF-based HIV drug, Odefsey, for the treatment of certain HIV-1 afflicted patients. Company & Industry OverviewsWhat Is a Bridging Study?
A bridging study on a drug is an additional study performed in a new region to provide clinical data on safety, efficacy, dosage, and dose regimen. Company & Industry OverviewsAbbVie’s Therapies in Virology, Neurology, and Women’s Health
In addition to its Oncology and Immunology segments, AbbVie is focused on launching innovative therapies in its Virology, Neurology, and Women’s Health segments. Company & Industry OverviewsBioMarin’s Business Model and Its 3 Sources of Revenue
Let’s discuss BioMarin’s business model. It derives revenue from three sources, including product revenue. The latter accounts for ~98% of total revenue. MiscellaneousMerck Will Soon See a Decision on Its New Hepatitis C Therapy
The FDA has scheduled the Prescription Drug User Fee Act (or PDUFA) date for Merck’s new hepatitis C combination therapy for January 28, 2016. MiscellaneousHow Would Kyndrisa Treat Duchenne Muscular Dystrophy?
The FDA advisory committee has given an unfavorable opinion to Kyndrisa. But most analysts estimate the probability of FDA approval for the drug to be about 50%. MiscellaneousKanuma: An Innovative Enzyme Replacement Therapy for LAL-D
Alexion Pharmaceuticals’ Kanuma is an innovative enzyme replacement therapy for patients suffering with lysosomal acid lipase deficiency (or LAL-D). Company & Industry OverviewsNovo Nordisk: An Investor’s Guide to a Leading Biotech Company
Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world. Company & Industry OverviewsAlexion Pharmaceuticals’ Cost Structure and EBITDA Margins
Mature biotechnology companies generally earn EBITDA margins of about 30% to 40%. Company & Industry OverviewsVertex Pharmaceuticals’ Cost Structure and EBITDA Margins
While mature biotechnology companies with drugs in multiple disease segments earn an average of 30%–40% EBITDA, margins of companies targeting only rare diseases can vary due to unique business models. Company & Industry OverviewsAlexion Pharmaceuticals Diversifies Its Research Pipeline
Alexion Pharmaceuticals (ALXN) has strengthened its drug pipeline by diversifying its research programs across the metabolic disorder segment. Company & Industry OverviewsVertex Has Strong Research and Development Pipeline
As part of its research and development, Vertex Pharmaceuticals (VRTX) has been actively exploring new cystic fibrosis (or CF) drugs as well as other indications for its existing drug Kalydeco. Company & Industry OverviewsAlexion Pharmaceuticals Expands Soliris Labels
Alexion Pharmaceuticals is actively involved in expanding the approved labels for its flagship product Soliris. Company & Industry OverviewsVertex Pharmaceuticals’ New Drug Orkambi Receives FDA Approval
On July 2, 2015, the FDA (U.S. Food and Drug Administration) approved Orkambi, a combination drug of lumacaftor and ivacaftor, for treating cystic fibrosis (or CF) patients. Company & Industry OverviewsVertex Pharmaceuticals’ 3-Pronged Business Model
Vertex Pharmaceuticals’ (VRTX) business model includes revenues in three areas: products, royalties, and collaboration. There’s significant variability in royalty and collaboration revenues. Company & Industry OverviewsAmgen’s Key Risks
Amgen’s key risks include market erosion due to generic competition for Neulasta and Neupogen. Its restructuring also involves a reduction of about 3,500–4,000 employees. Company & Industry OverviewsAmgen Develops World-Class Manufacturing Capability
Enhancing its manufacturing capability, Amgen has launched a next-generation bio-manufacturing facility in Singapore and plans to set up more in the coming years. Company & Industry OverviewsAmgen’s Research and Development Strategy
Amgen (AMGN) has adopted a well-structured research and development strategy focused on inflammation, metabolism, bone, and cardiovascular diseases. Company & Industry OverviewsRegeneron: An Investor’s Overview to a Leading Biotech Company
With a market capitalization of $50.7 billion, Regeneron is one of the country’s major biotechnology companies. Its products and pipeline candidates focus on cancer, eye diseases, and cardiovascular diseases. Company & Industry OverviewsAmgen: An Investor’s Overview to a Leading Biotech Company
An overview of global biotechnology company Amgen shows a market capitalization of $127.2 billion. Headquartered in Thousand Oaks, California, Amgen has a presence in 75 countries. Company & Industry OverviewsCelgene’s EBITDA Margins Surpass Competitors
Celgene’s EBITDA margins were lower than those of its competitors. Its R&D investment appears to be higher than its peers, and its SG&A expenses have risen. Company & Industry OverviewsIntroducing Celgene, a Leading Biotech Company
Celgene has consistently delivered breakthrough innovations in biotechnology and has as actively pursued acquisitions of companies for access to compounds. Company & Industry OverviewsGilead: Global Leader in the HIV Market
Gilead Sciences (GILD), a biotechnology leader in the human immunodeficiency virus, or HIV, market, offers drugs to eight out of every ten HIV naïve patients in the US. Company & Industry OverviewsAn Overview of Gilead Sciences’ Business Model
Gilead Sciences’ business model consists of product sales in the HIV and HCV markets, as well as royalty, contract, and other revenues. Company & Industry OverviewsGilead Sciences: Investor’s Overview of a Leading Biotech Company
The strong leadership of Gilead’s talented scientists has enabled the company to consistently deliver innovative therapies in the market. Company & Industry OverviewsAn Overview of Biogen’s Business Model
A leader in the development of multiple sclerosis treatments, Biogen earned 82.5% of its total revenues from its MS drugs in 2014. Company & Industry OverviewsMarket Entry Strategies for Biotechnology in Europe
When a US biotechnology company uses market entry strategies to launch its drug directly in the European market, it has to bear all the expenses related to the drug approval process in Europe. Company & Industry OverviewsSources of External Capital for the Biotechnology Industry
In the early stages of their life cycles, most biotechnology companies are financed by venture capital, which typically comes from wealthy investors who invest in startup companies. Company & Industry OverviewsHow Does Competition Impact the Biotechnology Industry?
The biotechnology sector is witnessing intense competition with big pharmaceutical companies entering into collaborations and mergers and acquisitions with biotechnology companies. Company & Industry OverviewsCommercial Growth Drivers of the Biotechnology Industry
After 2012, the biotechnology industry (IBB) had a period of solid growth, mainly driven by novel scientific inventions and aggressive commercial distribution. Company & Industry OverviewsSocial Factors That Impact the Biotechnology Industry
The aging Baby Boomer population in the United States is one of the social factors driving the US healthcare industry. By 2030, Americans over 55 will be 31% of the population. Company & Industry OverviewsEconomic Factors That Affect the Biotechnology Industry
Compared to pure-play pharmaceutical companies, the biotechnology industry is more sensitive to economic factors such as changes in GDP, interest rates, and exchange rates. Company & Industry OverviewsHow Are Drugs Classified?
The two main classifications for drugs are chemical compound drugs and biologics. Medicinal drugs are broadly classified as prescription drugs and over-the-counter drugs. Company & Industry OverviewsAnalyzing Pfizer’s Business Segments
Pfizer (PFE) is one of the oldest and largest pharmaceutical companies in the US. The company deals in two major business segments. Company & Industry OverviewsWhere Does Johnson & Johnson Stand in the Industry?
Estimates suggest that Johnson & Johnson’s forward PE ratio increased from 15.5x in 2014 to 16.1x in 2015. The PE ratio is hovering around 19x for the industry. Company & Industry OverviewsWhat Risks Does Johnson & Johnson Face?
Johnson & Johnson (JNJ) faces a unique combination of risks. The risks are in addition to specific risks in the pharmaceutical industry. Company & Industry OverviewsWhat it takes to be called ‘big pharma’
Pharmaceutical companies either deal with patented drugs, generic drugs, or both. Most big pharma companies deal with both.